X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis Fact Sheet, Novartis Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Novartis Fact Sheet   (NVRT)

Here is the latest financial fact sheet of Novartis. For more details, see the Novartis quarterly results and Novartis share price and chart. For a sector overview, read our pharmaceuticals sector report.

NOVARTIS Price History

Price Rs 626.7
Mkt Cap Rs m 210,216
Vol '000 2.8
P/E X 268.3
P/CF X 345.7
EPS (TTM) Rs 2.3
% ch % 0.6
No. of shares m 335.46
% ch week % 0.9
% ch 1-mth % -4.0
% ch 12-mth % -0.2
52 week H/L Rs 698.0/579.0
(As on May 25, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NOVARTIS Financials

No. of Mths
Year Ending
12
Mar-13
12
Mar-14
12
Mar-15
12
Mar-16
12
Mar-17
5-Yr Chart
Click to enlarge
NOVARTIS EQUITY SHARE DATA
High Rs934605760982855 
Low Rs565361438556666 
Sales per share (Unadj.) Rs282.7269.8273.3215.8219.0 
Earnings per share (Unadj.) Rs37.530.824.862.019.1 
Diluted earnings per shareRs3.62.92.45.91.7 
Cash flow per share (Unadj.) Rs38.632.026.063.120.3 
Dividends per share (Unadj.) Rs10.0010.0010.0010.0010.00 
Adj. dividends per shareRs0.950.950.950.950.89 
Dividend yield (eoy) %1.32.11.71.31.3 
Book value per share (Unadj.) Rs281.7300.8313.5373.5307.0 
Adj. book value per shareRs26.828.729.935.627.4 
Shares outstanding (eoy) m31.9631.9631.9631.9629.96 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x2.71.82.23.63.5 
Avg P/E ratio x20.015.724.212.439.8 
P/CF ratio (eoy) x19.415.123.012.237.5 
Price / Book Value ratio x2.71.61.92.12.5 
Dividend payout %26.732.440.416.152.4 
Avg Mkt Cap Rs m23,95415,43319,14724,58022,779 
No. of employees `0001.41.31.20.80.7 
Total wages/salary Rs m1,6231,7422,0001,5671,393 
Avg. sales/employee Rs Th6,555.66,663.37,236.09,172.59,736.2 
Avg. wages/employee Rs Th1,177.81,346.11,657.22,083.22,066.8 
Avg. net profit/employee Rs Th868.9761.4655.42,636.8849.0 
NOVARTIS INCOME DATA
Net Sales Rs m9,0348,6228,7346,8986,562 
Other income Rs m8329511,076809702 
Total revenues Rs m9,8669,5749,8107,7077,264 
Gross profit Rs m900-13-39-113259 
Depreciation Rs m3637403536 
Interest Rs m23227 
Profit before tax Rs m1,694899996659917 
Minority Interest Rs m00000 
Prior Period Items Rs m84396165170 
Extraordinary Inc (Exp) Rs m00-631,6960 
Tax Rs m581310306389345 
Profit after tax Rs m1,1979857911,983572 
Gross profit margin %10.0-0.2-0.4-1.63.9 
Effective tax rate %34.334.530.759.037.6 
Net profit margin %13.311.49.128.78.7 
NOVARTIS BALANCE SHEET DATA
Current assets Rs m10,33510,61010,63412,6379,731 
Current liabilities Rs m2,1222,1222,1072,0451,830 
Net working cap to sales %90.998.597.6153.6120.4 
Current ratio x4.95.05.06.25.3 
Inventory Days Days4544423849 
Debtors Days Days3333352725 
Net fixed assets Rs m10279856957 
Share capital Rs m160160160160141 
"Free" reserves Rs m8,8419,4529,85911,7769,056 
Net worth Rs m9,0029,61410,02011,9369,196 
Long term debt Rs m00000 
Total assets Rs m11,41212,02112,46114,32611,499 
Interest coverage x771.1334.0475.1314.7128.4 
Debt to equity ratio x00000 
Sales to assets ratio x0.80.70.70.50.6 
Return on assets %10.58.26.413.95.0 
Return on equity %13.310.27.916.66.2 
Return on capital %19.813.511.019.910.1 
Exports to sales %0.60.90.90.90 
Imports to sales %19.421.814.221.80 
Exports (fob) Rs m507980600 
Imports (cif) Rs m1,7491,8771,2441,5030 
Fx inflow Rs m125144149186129 
Fx outflow Rs m2,1372,3351,6451,8211,734 
Net fx Rs m-2,012-2,191-1,497-1,635-1,605 
NOVARTIS CASH FLOW
From Operations Rs m 74 -46 -596 566 -380 
From Investments Rs m -161 222 7,189 -6,305 4,208 
From Financial Activity Rs m -373 -378 -377 -386 -3,318 
Net Cashflow Rs m -460 -202 6,217 -6,125 510 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 75.0%
Indian inst/Mut Fund 2.0%
FIIs 1.6%
ADR/GDR 0.0%
Free float 21.5%
Shareholders 41,647
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Sandoz House, Shivsagar Estate, Dr. Annie Besant Road, Mumbai-18
E-MAIL girish.tekchandani@novartis.com WEB www.novartis.in
TELEPHONE (022) 2495 8400 FAX (022) 2495 0221
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Sharepro Serv., 13 AB, Samhita Warehousing, Andheri (E), Mumbai-72
AUDITOR Lovelock and Lewes
CHM: C. Snook COMP SEC: Girish Tekchandani YEAR OF INC: 1947 BSE CODE: 500672 FV (Rs): 5 DIV YIELD (%): 0.1

More Pharmaceuticals Company Fact Sheets:   PLETHICO PHARMA  ORCHID PHARMA LTD  GLENMARK PHARMA  SUVEN LIFE  NATCO PHARMA  

Compare NOVARTIS With:   PLETHICO PHARMA  ORCHID PHARMA LTD  GLENMARK PHARMA  SUVEN LIFE  NATCO PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Up; ONGC & Tata Steel Top Gainers(Closing)

Indian share markets ended the day on a strong note. At the closing bell, the BSE Sensex finished higher by 262 points. While, the NSE Nifty finished up by 91 points.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NOVARTIS

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS